Cabot Giese Aff
| Tournament | Round | Opponent | Judge | Cites | Round Report | Open Source | Edit/Delete |
|---|---|---|---|---|---|---|---|
| Little Rock Central | 2 | JPG Pourciau | Mills, Alex |
|
|
|
| Tournament | Round | Report |
|---|---|---|
| Little Rock Central | 2 | Opponent: JPG Pourciau | Judge: Mills, Alex 1AC 1NC |
To modify or delete round reports, edit the associated round.
Cites
| Entry | Date |
|---|---|
Covid and IPRTournament: Little Rock Central | Round: 2 | Opponent: JPG Pourciau | Judge: Mills, Alex For pandemics and other public health emergencies, patents’ mix of costs and benefits is misaligned with what is needed for an effective policy response. The basic patent bargain, even when well struck, is to pay for more innovation down the road with slower diffusion of innovation today. In the context of a pandemic, that bargain is a bad one and should be rejected entirely. Here the imperative is to accelerate the diffusion of vaccines and other treatments, not slow it down. Giving drug companies the power to hold things up by blocking competitors and raising prices pushes in the completely wrong direction. | 9/25/21 |
DefinitionTournament: Little Rock Central | Round: 2 | Opponent: JPG Pourciau | Judge: Mills, Alex The definition of intellectual property rights is any and all rights associated with intangible assets owned by a person or company and protected against use without consent. Intangible assets refer to non-physical property, including right of ownership in intellectual property | 9/25/21 |
GenericsTournament: Little Rock Central | Round: 2 | Opponent: JPG Pourciau | Judge: Mills, Alex The Department of Health and Human Services (HHS) has taken a number of actions to increase competition and end the gaming of regulatory processes that may keep drug prices artificially inflated or delay generic, branded, or biosimilar competition. These efforts, which were in motion before the announcement of the blueprint, include increasing the number of generic drugs and accelerating approval of generic drugs.1 Studies show that greater generic competition is associated with lower prices. Based on a study in 2017, the relative price of a generic medication to the branded medication decreases appreciably when there are 3 or more manufacturers of the generic version. The researchers found that the relative generic-to-brand price was 87, 77, and 60 when there were 1, 2, and 3 generic manufacturers, respectively. With each additional manufacturer, the relative prices decreased at a slower rate. | 9/25/21 |
Lack of Med DeathsTournament: Little Rock Central | Round: 2 | Opponent: JPG Pourciau | Judge: Mills, Alex More than 13 of American adults -- or about 34 million people -- report knowing of at least one friend or family member in the past five years who died after not receiving needed medical treatment because they were unable to pay for it, based on a new study by Gallup and West Health. Nonwhites, those in lower-income households, those younger than 45, and political independents and Democrats are all more likely to know someone who has died under these circumstances. | 9/25/21 |
Limited Covid VaccinesTournament: Little Rock Central | Round: 2 | Opponent: JPG Pourciau | Judge: Mills, Alex High-income countries have dominated the limited supply of COVID-19 vaccines, leaving low and middle-income countries (LMICs) with limited, if any, supplies of these life-saving countermeasures.1 The cause of this is two-fold: 1) insufficient doses of vaccine to meet the global demand, and 2) procurement of those limited doses which do exist has been dominated by a small number of high-income countries. The result is a deep and growing inequality in access to vaccines for COVID-19. A potential solution is to empower manufacturers, particularly those based in LMICs, to begin making COVID-19 vaccines, to expand global supply. However, intellectual property rights create a clear barrier to this solution. A dense web of intellectual property exists over the vaccines and the manufacturing platforms used to make them.2 This web is both formal and informal; the manufacturing platform used to manufacture a vaccine is protected by numerous patents, while manufacturing methods and techniques (know-how) are protected informally as trade secrets. | 9/25/21 |
Monopolistic PracticesTournament: Little Rock Central | Round: 2 | Opponent: JPG Pourciau | Judge: Mills, Alex If we work to reduce IPR protections, we can increase the amount of generic | 9/25/21 |
Open Source
| Filename | Date | Uploaded By | Delete |
|---|